Format

Send to

Choose Destination
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72-81. doi: 10.1016/j.jacl.2014.03.002.

An assessment by the Statin Intolerance Panel: 2014 update.

Author information

1
Division of Endocrinology, Diabetes, and Metabolism, Duke University Medical Center, 201 Trent Drive, Baker House 281, Durham, NC 27710, USA. Electronic address: john.guyton@duke.edu.
2
Louisville Metabolic and Atherosclerosis Research Center, Louisville KY, USA.
3
Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, USA.
4
Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Abstract

This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.

KEYWORDS:

Drug intolerance; Patient-centered medicine; Statin adverse effects; Statin safety; Statins

PMID:
24793444
DOI:
10.1016/j.jacl.2014.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center